Loading stock data…
Legend Biotech Corporation (LEGN)
$29.39+0.70 (+2.44%)
After Hours$29.45+0.06 (+0.20%)· Last close Jun 29
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Legend Biotech Corporation in the Healthcare sector is trading at $29.39 with a market capitalization of $6.3B. Wall Street consensus targets $57.43 (15 analysts), implying a +95.4% move over the next 12 months. The stock is currently 35% below its 52-week high of $45.30, remaining 15.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +95.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $305.10M↓ | $306.38M↑ | $272.33M↑ | $255.06M↑ | $195.00M |
| Gross Profit | $129.20M↓ | $182.92M↑ | $157.02M | $157.07M↑ | $123.70M |
| Operating Income | -$49.80M↓ | -$20.60M↑ | -$43.45M↓ | -$21.88M↑ | -$51.70M |
| Net Income | -$54.30M↓ | -$30.82M↑ | -$39.69M↑ | -$125.38M↓ | -$101.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.85%
Volume
Today's trading volume
1.20M
Recent News
Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Legend Biotech Corporation (NASDAQ:LEGN) is among the best healthcare stocks. TheFly reported on June 3 that UBS increased its price target on LEGN to $49 from $31 while reiterating a Buy rating on the stock. The firm cited […]
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in its business and a share price that looks like a mistake.
Legend Biotech (LEGN) Reports a Complete Response in Five of Six Patients at Its Highest Dose
Legend Biotech Corporation (NASDAQ:LEGN) is one of the most promising healthcare stocks according to Wall Street analysts. Legend Biotech Corporation (NASDAQ:LEGN) recently announced the first human proof-of-concept results for LB2501, its experimental next-generation cancer therapy. The company presented the data at the European Hematology Association 2026 Congress. Legend said LB2501 is designed for patients with […]
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Interim US-Iran Deal Lifts Risk Sentiment
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively tra
Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates
By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Association 2026 Congress taking place on June 11-14, 2026, in Stockholm, Sweden. The global TENACITY-01 study had an 85.7% overall response rate, with a complete remission rate of 71.4% in adults […] The post Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates appeared first on ExecEdge.